June 30, 2015

Not intended for U.S. and UK Media

Bayer Submits an Application for Market Authorization of Recombinant Factor VIII Product as a Treatment of Hemophilia A in Japan

Berlin, June 30, 2015 - Bayer HealthCare today announced that Bayer Yakuhin,
Ltd., Osaka, Japan, has submitted an application for marketing authorization
for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, as a treatment of
hemophilia A. BAY 81-8973 is a full-length recombinant factor VIII which has
shown clinical benefit of efficacy when used for prophylaxis twice or three
times per week, with standard dosages.

"With more than two decades of experience in Japan, Bayer has a strong
commitment to the hemophilia community", said Dr. Joerg Moeller, Member of the
Bayer HealthCare Executive Committee and Head of Global Development. "The
submission of BAY 81-8973 in Japan is an important step forward in our
continued efforts to improve treatment options for people with hemophilia A."

The submission was based on positive results from three Phase III trials in
children, adolescents and adults including a total of 204 subjects. The LEOPOLD
II clinical trial demonstrated the superiority of prophylaxis versus on-demand
therapy with BAY 81-8973. Results show a 93.3 percent reduction in median
annualized bleeding rate (ABR) in the twice-per-week prophylaxis arm versus
on-demand and a 96.7 percent reduction in the three-times-per-week arm versus
on-demand. Patients in this study were randomized between the three treatment
arms. The actual median ABRs observed were four bleeds when treated two times
per week and two bleeds when treated three times versus 60 in the on-demand
group. Patients treated in both the twice-per-week arm and the
three-times-per-week arm maintained adequate bleeding control while using 20 to
40 IU/KG. When used on-demand, 95 percent of bleeds were controlled with one or
two infusions. No clinically relevant treatment-related adverse events occurred
and no inhibitor formation was observed. In LEOPOLD Kids (pediatric trial)
including 51 pre-treated children <12 years of age, BAY 81-8973 demonstrated
good efficacy with twice or three times per week or every other day prophylaxis
regimens, and no inhibitors were observed. A clinical study in previously
untreated patients is ongoing. Bayer presented the LEOPOLD II results at the
World Federation of Hemophilia (WFH) Congress in May 2014.

About LEOPOLD

The LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A
Disease) Clinical Development Program consists of 3 multinational clinical
trials designed to evaluate the pharmacokinetics, efficacy, and safety of BAY
81-8973 in subjects with severe hemophilia A (<1% FVIII:C).

LEOPOLD I is a randomized, open-label, cross-over Phase III study in males aged
12-65 years. The objectives were to demonstrate the efficacy and safety of BAY
81-8973 when used as prophylaxis, for the treatment of bleeding episodes, and
for maintaining hemostasis during surgery. LEOPOLD II is a randomized,
cross-over, open-label trial also in male subjects aged 12 to 65 years. In this
Phase III study, 80 subjects were randomized to receive BAY 81-8973 either as a
low-dose prophylaxis regimen (20-30 IU/kg; n=28) twice-per-week, high-dose
prophylaxis (30-40 IU/kg; n=31) three-times-per-week, or on-demand (n=21). The
primary objective was to demonstrate the superiority of prophylaxis versus
on-demand therapy, with the primary endpoint being bleeding frequency at 12
months. LEOPOLD Kids is an open-label, non-randomized Phase III study to
evaluate the efficacy and safety of BAY 81-8973 for prophylaxis, treatment of
bleeds, and surgical management in previously treated children <=12 years of
age.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia is a
largely inherited bleeding disorder. Hemophilia A, the most common type of
hemophilia, is caused by deficient or defective blood coagulation proteins,
known as Factor VIII. Hemophilia A is characterized by prolonged or spontaneous
bleeding, especially into the muscles, joints or internal organs.

About Hematology at Bayer HealthCare

Bayer HealthCare is committed to delivering Science For A Better Life by
advancing a portfolio of innovative treatments. Hematology at Bayer HealthCare
includes an approved treatment for hemophilia A and numerous compounds in
various stages of development for hemophilia, sickle cell anemia, and other
blood and bleeding disorders. Together, these compounds reflect the company's
commitment to research and development for these indications, prioritizing
specific targets for intervention with the potential to improve the way that
rare blood and bleeding disorders are treated.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of around EUR 20.0 billion (2014), is one of the
world's leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31,
2014) and is represented in more than 100 countries. More information is
available at www.healthcare.bayer.com.

Our online press service is just a click away: press.healthcare.bayer.com
Follow us on Facebook: http://www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerHealthCare

Find more information at www.bayerpharma.com.

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.